PharmaCyte Biotech
PMCB
30 hedge funds and large institutions have $9.93M invested in PharmaCyte Biotech in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
8% less call options, than puts
Call options by funds: $522K | Put options by funds: $566K
3% less funds holding
Funds holding: 31 → 30 (-1)
5.91% less ownership
Funds ownership: 24.02% → 18.11% (-5.9%)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
17% less capital invested
Capital invested by funds: $12M → $9.93M (-$2.03M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$346K |
| 2 |
FIA
FNY Investment Advisers
New York
|
+$89.1K |
| 3 |
Jane Street
New York
|
+$59.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$50.1K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$49.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
-$2.44M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.34M |
| 3 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
-$480K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$215K |
| 5 |
Millennium Management
New York
|
-$60K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWA
26
TCI Wealth Advisors
Tucson,
Arizona
| $9 | – | – | – |
|
|
CA
27
Clearstead Advisors
Cleveland,
Ohio
| $9 | +$9 | +3 | New |
|
|
SC
28
Shay Capital
New York
| – | -$2.44M | -1,015,666 | Closed |
|
|
CAG
29
Csenge Advisory Group
Clearwater,
Florida
| – | -$480K | -200,104 | Closed |
|
|
30
Group One Trading
Chicago,
Illinois
| – | -$215K | -75,052 | Closed |
|
|
31
Millennium Management
New York
| – | -$60K | -25,018 | Closed |
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$47.6K | -16,624 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$152 | -53 | -35% |
|
|
FDCDDQ
34
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$17 | -7 | Closed |
|
|
NA
35
NewEdge Advisors
New Orleans,
Louisiana
| – | +$6 | +2 | New |
|
PMCB Hedge Fund Activity: Q4 2022 in Review
30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q4 2022, worth a combined $9.93M — down 17% from $12M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PMCB and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was K2 Principal Fund, adding an estimated $346K. The largest seller was Shay Capital, exiting entirely with an estimated $2.44M sold.
- 30 institutional investors held PharmaCyte Biotech (PMCB) as of Q4 2022, down from 31 in Q3 2022.
- Funds reported $9.93M of PharmaCyte Biotech stock for Q4 2022, down 17% quarter-over-quarter.
- 6 funds opened new PharmaCyte Biotech positions in Q4 2022 and 7 closed out, a net change of -1 holder.
- The largest PharmaCyte Biotech buyer in Q4 2022 was K2 Principal Fund, an estimated $346K added.
- The largest PharmaCyte Biotech seller in Q4 2022 was Shay Capital, an estimated $2.44M sold.
Based on aggregated 13F filings for Q4 2022.